Ani Pharmaceuticals (ANIP) Convertible Debt (2010 - 2019)

Ani Pharmaceuticals (ANIP) has 9 years of Convertible Debt data on file, last reported at $117.6 million in Q3 2019.

• For the quarter ending Q3 2019, Convertible Debt fell 12.33% year-over-year to $117.6 million; the trailing twelve-month figure through Sep 2019 stood at $117.6 million (down 12.33% YoY), and the FY2018 full-year result was $112.5 million, down 12.28% from the prior year.
• Convertible Debt grew to $117.6 million in Q3 2019, from $115.9 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $134.1 million in Q3 2018 to a low of $112.2 million in Q1 2015.
• A 5-year average of $120.2 million and a median of $117.6 million in 2019 frame the typical range for Convertible Debt.
• Across the five-year window, Convertible Debt advanced 6.46% in 2015 and slipped 12.33% in 2019, its largest moves.
• Tracing ANIP's Convertible Debt over 5 years: stood at $113.4 million in 2015, then rose by 6.36% to $120.6 million in 2016, then gained by 6.27% to $128.2 million in 2017, then slipped by 12.28% to $112.5 million in 2018, then grew by 4.56% to $117.6 million in 2019.
• Business Quant data shows ANIP's Convertible Debt at $117.6 million in Q3 2019, $115.9 million in Q2 2019, and $114.2 million in Q1 2019.